BioSpace News Archive

CareDx, Inc. today announced that the Company will participate in two upcoming investor conferences.

Arbutus Biopharma Corporation today announced that the Arbutus management team will present at and host one-on-one meetings at the following upcoming investor conference being held in New York.

NanoViricides, Inc., a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its development of a first-in-class, broad-spectrum antiviral agent that could revolutionize treatment of viral infections including RSV, COVID, Influenzas and other viruses.

Skinvisible Pharmaceuticals, Inc., an innovative pharmaceutical research and development company, announced a major advancement in the battle against obesity.

Affimed N.V. announced that the FDA has granted Fast Track designation to the combination of its innate cell engager AFM24 with atezolizumab for the treatment of patients with advanced and/or metastatic non-small cell lung cancer not harboring any activating EGFR mutations after progression on PD-1 targeted therapy and platinum-based chemotherapy.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, announced that the Company will participate in fireside chats at the following upcoming investor events.

IGM Biosciences, Inc. announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York.

MediWound Ltd., the global leader in next-generation enzymatic therapeutics for tissue repair, announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Invivyd, Inc. announced that it will present preliminary, subset analyses from the CANOPY Phase 3 clinical trial of VYD222 for pre-exposure prophylaxis of COVID-19 at the 2024 American Society of Clinical Oncology Annual Meeting and at the 2024 American Transplant Congress.

Atea Pharmaceuticals, Inc. announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Wednesday, June 5, 2024 at 10:30 a.m. ET in New York.